Peter N. Morcos

5.0k total citations · 3 hit papers
48 papers, 3.6k citations indexed

About

Peter N. Morcos is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Hepatology. According to data from OpenAlex, Peter N. Morcos has authored 48 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Pulmonary and Respiratory Medicine, 25 papers in Oncology and 12 papers in Hepatology. Recurrent topics in Peter N. Morcos's work include Lung Cancer Treatments and Mutations (32 papers), Lung Cancer Research Studies (18 papers) and Hepatitis C virus research (11 papers). Peter N. Morcos is often cited by papers focused on Lung Cancer Treatments and Mutations (32 papers), Lung Cancer Research Studies (18 papers) and Hepatitis C virus research (11 papers). Peter N. Morcos collaborates with scholars based in United States, Switzerland and United Kingdom. Peter N. Morcos's co-authors include Sai‐Hong Ignatius Ou, Bogdana Balas, Sophie Golding, Shirish M. Gadgeel, Ali Zeaiter, Jin Seok Ahn, Alice T. Shaw, Dong‐Wan Kim, Tony Mok and Rafael Rosell and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Peter N. Morcos

47 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

2017 1.6k citations Solange Peters, D. Ross Camidge et al. New England Journal of Medicine profile →
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study

2014 538 citations Shirish M. Gadgeel, Leena Gandhi et al. The Lancet Oncology profile →
Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study

2015 430 citations Sai‐Hong Ignatius Ou, Jin Seok Ahn et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Peter N. Morcos

Since Specialization

Citations

This map shows the geographic impact of Peter N. Morcos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter N. Morcos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter N. Morcos more than expected).

Fields of papers citing papers by Peter N. Morcos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter N. Morcos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter N. Morcos. The network helps show where Peter N. Morcos may publish in the future.

Co-authorship network of co-authors of Peter N. Morcos

This figure shows the co-authorship network connecting the top 25 collaborators of Peter N. Morcos. A scholar is included among the top collaborators of Peter N. Morcos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter N. Morcos. Peter N. Morcos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first‐line treatment of anaplastic lymphoma kinase–positive non‐small cell lung cancer 2021 ·CPT Pharmacometrics & Systems Pharmacology ·Joy Hsu, (unknown), Elena Guerini, Bogdana Balas, Walter Bordogna, Peter N. Morcos, Nicolas Frey	8
2	Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study 2019 ·The Lancet Respiratory Medicine ·Caicun Zhou, Sang-We Kim, Thanyanan Reungwetwattana, Jianying Zhou, Yiping Zhang, Jianxing He, Jin-Ji Yang, Ying Cheng, Se‐Hoon Lee, Lilian Bu, Tingting Xu, Li Yang, Chao Wang, Ting Liu, Peter N. Morcos, You Lu, Li Zhang	186
3	Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer 2019 ·Lung Cancer ·Sai‐Hong Ignatius Ou, Shirish M. Gadgeel, Fabrice Barlési, James Chih‐Hsin Yang, Luigi De Petris, Dong‐Wan Kim, Ramaswamy Govindan, Anne‐Marie C. Dingemans, Lucio Crinò, H. Léna, Sanjay Popat, Jin Seok Ahn, Éric Dansin, Emmanuel Mitry, (unknown), Walter Bordogna, Bogdana Balas, Peter N. Morcos, Alice T. Shaw	21
4	Model‐Informed Drug Development Approach to Expedite Approval: Case of Alectinib in First‐Line Anaplastic Lymphoma Kinase + Non‐Small Cell Lung Cancer 2019 ·Clinical Pharmacology & Therapeutics ·Peter N. Morcos, Jiang Liu, Gideon M. Blumenthal, Hong Zhao	4
5	Primary results of ALESIA: A randomised, phase III, open-label study of alectinib vs crizotinib in Asian patients with treatment-naïve ALK+ advanced NSCLC 2018 ·Annals of Oncology ·C. Zhou, You Lü, (unknown), Thanyanan Reungwetwattana, Jianying Zhou, Y. Zhang, Jianxing He, Jin‐Ji Yang, Ying Cheng, (unknown), (unknown), Tingting Xu, Lei Yang, (unknown), Peter N. Morcos, Emmanuel Mitry, Tian Liu, L. Zhang	7
6	Primary results of ALESIA: Phase III, randomised open-label study of alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naïve ALK+ advanced non-small-cell lung cancer (NSCLC) 2018 ·Annals of Oncology ·C. Zhou, You Lü, (unknown), Thanyanan Reungwetwattana, Jianying Zhou, Y. Zhang, Jianxing He, Jin‐Ji Yang, Ying Cheng, (unknown), (unknown), Tingting Xu, Lei Yang, (unknown), Peter N. Morcos, Emmanuel Mitry, (unknown)	5
7	Exposure–response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer 2018 ·Cancer Chemotherapy and Pharmacology ·Peter N. Morcos, (unknown), (unknown), Elena Guerini, Joy Hsu, Walter Bordogna, Bogdana Balas, François Mercier	24
8	Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer (NSCLC). 2018 ·Journal of Clinical Oncology ·Sai‐Hong Ignatius Ou, Leena Gandhi, Shirish M. Gadgeel, Fabrice Barlési, James Chih‐Hsin Yang, Luigi De Petris, Dong‐Wan Kim, Ramaswamy Govindan, Anne‐Marie C. Dingemans, Lucio Crinò, H. Léna, Sanjay Popat, Jin Seok Ahn, Éric Dansin, Ali Zeaiter, Bárbara Müller, H. Johannsdottir, Bogdana Balas, Peter N. Morcos, Alice T. Shaw	5
9	Alectinib (ALC) vs crizotinib (CRZ) in treatment-naïve ALK+ non-small-cell lung cancer (NSCLC): Asian vs non-Asian subgroup analysis of the ALEX study 2017 ·Annals of Oncology ·Tony Mok, Solange Peters, D. Ross Camidge, S-H.I. Ou, Jin Seok Ahn, E.H. Tan, (unknown), Jin Sun Lee, Byoung Chul Cho, Sarayut Lucien Geater, Virote Sriuranpong, Jcm Ho, (unknown), Ali Zeaiter, Bogdan Balas, (unknown), Emmanuel Mitry, Peter N. Morcos, Dongwook Kim	8
10	Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK -positive Non-Small Cell Lung Cancer 2017 ·Journal of Thoracic Oncology ·James Chih‐Hsin Yang, Sai‐Hong Ignatius Ou, Luigi De Petris, Shirish M. Gadgeel, Leena Gandhi, Dong‐Wan Kim, Fabrice Barlési, Ramaswamy Govindan, Anne‐Marie C. Dingemans, Lucio Crinò, H. Léna, Sanjay Popat, Jin Seok Ahn, Éric Dansin, Sophie Golding, Walter Bordogna, Bogdana Balas, Peter N. Morcos, Ali Zeaiter, Alice T. Shaw	65
11	Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies 2017 ·Cancer Chemotherapy and Pharmacology ·Peter N. Morcos, Katrijn Bogman, Stanislas Hubeaux, (unknown), Thorsten Ruf, Walter Bordogna, Sophie Golding, Ali Zeaiter, Markus Abt, Bogdana Balas	33
12	Progress in Prediction and Interpretation of Clinically Relevant Metabolic Drug-Drug Interactions: a Minireview Illustrating Recent Developments and Current Opportunities 2017 ·Current Pharmacology Reports ·Stephen Fowler, Peter N. Morcos, Yumi Cleary, Meret Martin‐Facklam, Neil Parrott, Michael Gertz, (unknown)	36
13	Metabolites of alectinib in human: their identification and pharmacological activity 2017 ·Heliyon ·(unknown), (unknown), (unknown), Yukako Tachibana, Miyuki Yoshida, Kenji Takanashi, Peter N. Morcos, (unknown), (unknown), Li Yu	18
14	Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer breakdown → 2017 ·New England Journal of Medicine ·Solange Peters, D. Ross Camidge, Alice T. Shaw, Shirish M. Gadgeel, Jin Seok Ahn, Dong‐Wan Kim, Sai‐Hong Ignatius Ou, M. Pérol, Rafał Dziadziuszko, Rafael Rosell, Ali Zeaiter, Emmanuel Mitry, Sophie Golding, Bogdana Balas, Johannes Noé, Peter N. Morcos, Tony Mok	1619
15	Updated efficacy and safety from the global phase II NP28673 study of alectinib in patients (pts) with previously treated ALK+ non-small-cell lung cancer (NSCLC) 2016 ·Annals of Oncology ·Fabrice Barlési, Anne‐Marie C. Dingemans, James Chih‐Hsin Yang, (unknown), (unknown), Luigi De Petris, Benjamin Hughes, H. Léna, Walter Bordogna, S Golding, Peter N. Morcos, Bogdan Balas, Ali Zeaiter, Dongwook Kim	11
16	Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis 2016 ·Hepatology International ·Edward Gane, Roman Rouzier, Tarek Hassanein, Catherine Stedman, Włodzimierz Mazur, Viera Kupčová, Sophie Le Pogam, Simon Eng, Athina Voulgari, Peter N. Morcos, Barbara J. Brennan, Astrid Scalori, James Thommes	5
17	Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study breakdown → 2015 ·Journal of Clinical Oncology ·Sai‐Hong Ignatius Ou, Jin Seok Ahn, Luigi De Petris, Ramaswamy Govindan, James Chih‐Hsin Yang, Brett Hughes, H. Léna, Denis Moro‐Sibilot, Alessandra Bearz, Santiago Viteri, Tarek Mekhail, Alexander I. Spira, Walter Bordogna, Bogdana Balas, Peter N. Morcos, Annabelle Monnet, Ali Zeaiter, Dong‐Wan Kim	430
18	Mericitabine and ritonavir‐boosted danoprevir with or without ribavirin in treatment‐naive HCV genotype 1 patients: INFORM ‐ SVR study 2014 ·Liver International ·Edward Gane, Paul J. Pockros, Stefan Zeuzem, Patrick Marcellin, (unknown), Coen Bernaards, Julian Q. Zhou, (unknown), R. Ballester, (unknown), Xiao Tong, Isabel Nájera, A Bertasso, Janet Hammond, (unknown), Peter N. Morcos, Patrick F. Smith, (unknown), Nancy S. Shulman	23
19	Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study breakdown → 2014 ·The Lancet Oncology ·Shirish M. Gadgeel, Leena Gandhi, Gregory J. Riely, Alberto Chiappori, Howard West, Michele C. Azada, Peter N. Morcos, (unknown), (unknown), Li Yu, Frédéric Boisserie, (unknown), Sophie Golding, (unknown), (unknown), Tomohiro Tanaka, Sai‐Hong Ignatius Ou	538
20	Influence of chronic hepatitis C infection on cytochrome P450 3a4 activity using midazolam as an in vivo probe substrate 2013 ·European Journal of Clinical Pharmacology ·Peter N. Morcos, (unknown), Barbara J. Brennan, Steven Blotner, Nancy S. Shulman, Patrick F. Smith	34

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact